New hope for inoperable liver cancer: targeted artery treatments show promise
NCT ID NCT06313203
First seen Feb 02, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This study is for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be removed by surgery. It compares two treatments delivered directly to the liver's blood supply—HAI-FUDR/DEX and SIRT—both given alongside standard chemotherapy. The goal is to shrink tumors enough to allow surgery later or to help people live longer. About 39 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Oslo University Hospital
RECRUITINGOslo, Oslo, 0424, Norway
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.